A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease

Marvin E. Reid, Amal El Beshlawy, Adlette Inati, Abdullah Kutlar, Miguel R. Abboud, Johnson Haynes, Richard Ward, Bruce Sharon, Ali T. Taher, Wally Smith, Deepa Manwani, Richard G. Ghalie

Research output: Contribution to journalArticle

37 Scopus citations

Fingerprint Dive into the research topics of 'A double-blind, placebo-controlled phase II study of the efficacy and safety of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease'. Together they form a unique fingerprint.

Medicine & Life Sciences